Advances in the management of peritoneal malignancies.

Cortés-Guiral, D. et al. Primary and metastatic peritoneal surface malignancies. Nat. Rev. Dis. Prim. 7, 91 (2021).

pubmed: 34916522 doi: 10.1038/s41572-021-00326-6

Sadeghi, B. et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88, 358–363 (2000).

pubmed: 10640968 doi: 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O

Chu, D. Z., Lang, N. P., Thompson, C., Osteen, P. K. & Westbrook, K. C. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 63, 364–367 (1989).

pubmed: 2910444 doi: 10.1002/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V

Jayne, D. G., Fook, S., Loi, C. & Seow-Choen, F. Peritoneal carcinomatosis from colorectal cancer. Br. J. Surg. 89, 1545–1550 (2002).

pubmed: 12445064 doi: 10.1046/j.1365-2168.2002.02274.x

Sugarbaker, P. H. Peritonectomy procedures. Ann. Surg. 221, 29–42 (1995).

pubmed: 7826158 pmcid: 1234492 doi: 10.1097/00000658-199501000-00004

Arquillière, J., Glehen, O. & Passot, G. Cytoreductive surgery in peritoneal carcinomatosis. J. Visc. Surg. 158, 258–264 (2021).

pubmed: 33487563 doi: 10.1016/j.jviscsurg.2020.12.012

Chi, D. S. et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol. Oncol. 94, 650–654 (2004).

pubmed: 15350354 doi: 10.1016/j.ygyno.2004.01.029

Glehen, O., Mohamed, F. & Gilly, F. N. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 5, 219–228 (2004).

pubmed: 15050953 doi: 10.1016/S1470-2045(04)01425-1

Glehen, O. et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients. Cancer 116, 5608–5618 (2010).

pubmed: 20737573 doi: 10.1002/cncr.25356

Speeten, K. V., der, Lemoine, L. & Sugarbaker, P. Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice. Pleura Peritoneum 2, 63–72 (2017).

pubmed: 30911634 pmcid: 6405035 doi: 10.1515/pp-2017-0003

Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L. & Montz, F. J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20, 1248–1259 (2002).

pubmed: 11870167 doi: 10.1200/JCO.2002.20.5.1248

Elias, D. et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J. Clin. Oncol. 28, 63–68 (2010).

pubmed: 19917863 doi: 10.1200/JCO.2009.23.9285

Kusamura, S. et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 156, e206363 (2021).

pubmed: 33502455 pmcid: 7841579 doi: 10.1001/jamasurg.2020.6363

Jacquet, P. & Sugarbaker, P. H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat. Res. 82, 359–374 (1996).

pubmed: 8849962 doi: 10.1007/978-1-4613-1247-5_23

Goere, D. et al. Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the peritoneal surface oncology group international (PSOGI). Int. J. Hyperthermia 33, 520–527 (2017).

pubmed: 28540827 doi: 10.1080/02656736.2017.1301576

Chirurgie, A. Fde et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann. Surg. Oncol. 17, 2370–2377 (2010).

doi: 10.1245/s10434-010-1039-7

Bakrin, N. et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur. J. Surg. Oncol. 39, 1435–1443 (2013).

pubmed: 24209430 doi: 10.1016/j.ejso.2013.09.030

Villeneuve, L. et al. A new internet tool to report peritoneal malignancy extent. PeRitOneal malignancy stage evaluation (PROMISE) application. Eur. J. Surg. Oncol. 42, 877–882 (2016).

pubmed: 27067193 doi: 10.1016/j.ejso.2016.03.015

Chapel, D. B. et al. Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases. Mod. Pathol. 34, 380–395 (2020).

pubmed: 33060816 doi: 10.1038/s41379-020-00688-4

Benzerdjeb, N. et al. Combined grade and nuclear grade are prognosis predictors of epithelioid malignant peritoneal mesothelioma: a multi-institutional retrospective study. Virchows Arch. 479, 927–936 (2021).

pubmed: 34169365 doi: 10.1007/s00428-021-03144-z

Panou, V. et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J. Clin. Oncol. 36, 2863–2871 (2018).

pubmed: 30113886 pmcid: 6804864 doi: 10.1200/JCO.2018.78.5204

Chirac, P. et al. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array. Hum. Pathol. 55, 72–82 (2016).

pubmed: 27184482 doi: 10.1016/j.humpath.2016.04.015

Alakus, H. et al. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. J. Transl. Med. 13, 122 (2015).

pubmed: 25889843 pmcid: 4422481 doi: 10.1186/s12967-015-0485-1

Joseph, N. M. et al. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. Mod. Pathol. 30, 246–254 (2017).

pubmed: 27813512 doi: 10.1038/modpathol.2016.188

Leblay, N. et al. BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas. J. Thorac. Oncol. 12, 724–733 (2017).

pubmed: 28034829 doi: 10.1016/j.jtho.2016.12.019

Shrestha, R. et al. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Med. 11, 8 (2019).

pubmed: 30777124 pmcid: 6378747 doi: 10.1186/s13073-019-0620-3

Deraco, M. et al. In Pathology of Peritoneal Metastases (eds Glehen, O. & Bhatt, A.) 117–129 (Springer, 2020) https://doi.org/10.1007/978-981-15-3773-8_6 .

Carbone, M. et al. BAP1 and cancer. Nat. Rev. Cancer 13, 153–159 (2013).

pubmed: 23550303 pmcid: 3792854 doi: 10.1038/nrc3459

Sugarbaker, P. H. et al. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann. Surg. 219, 109–111 (1994).

pubmed: 8129480 pmcid: 1243111 doi: 10.1097/00000658-199402000-00001

Carr, N. J. et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) mModified Delphi process. Am. J. Surg. Pathol. 40, 14–26 (2016).

pubmed: 26492181 doi: 10.1097/PAS.0000000000000535

Lin, Y. L. et al. Consensuses and controversies on pseudomyxoma peritonei: a review of the published consensus statements and guidelines. Orphanet J. Rare Dis. 16, 85 (2021).

pubmed: 33581733 pmcid: 7881689 doi: 10.1186/s13023-021-01723-6

Valasek, M. A. & Pai, R. K. An update on the diagnosis, grading, and staging of appendiceal mucinous neoplasms. Adv. Anat. Pathol. 25, 38–60 (2018).

pubmed: 29016471 doi: 10.1097/PAP.0000000000000178

Levine, E. A. et al. Prognostic molecular subtypes of low-grade cancer of the appendix. J. Am. Coll. Surg. 222, 493–503 (2016).

pubmed: 26821970 doi: 10.1016/j.jamcollsurg.2015.12.012

Vaira, M. et al. In Pathology of Peritoneal Metastases (eds Glehen, O. & Bhatt, A.) 163–173 (Springer, 2020).

Su, J. et al. Prognostic molecular classification of appendiceal mucinous neoplasms treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann. Surg. Oncol. 27, 1439–1447 (2020).

pubmed: 31980985 pmcid: 7147286 doi: 10.1245/s10434-020-08210-5

Moaven, O. et al. Clinical implications of genetic signatures in appendiceal cancer patients with incomplete cytoreduction/HIPEC. Ann. Surg. Oncol. 27, 5016–5023 (2020).

pubmed: 32705511 pmcid: 7674220 doi: 10.1245/s10434-020-08841-8

Ajani, J. A. et al. Gastric adenocarcinoma. Nat. Rev. Dis. Prim. 3, 17036 (2017).

pubmed: 28569272 doi: 10.1038/nrdp.2017.36

Gao, D. et al. Cdh1 regulates cell cycle through modulating the Claspin/Chk1 and the Rb/E2F1 pathways. Mol. Biol. Cell 20, 3305–3316 (2009).

pubmed: 19477924 pmcid: 2710831 doi: 10.1091/mbc.e09-01-0092

Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).

doi: 10.1038/nature13480

Cristescu, R. et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 21, 449–456 (2015).

pubmed: 25894828 doi: 10.1038/nm.3850

Wang, K. et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat. Genet. 46, 573–582 (2014).

pubmed: 24816253 doi: 10.1038/ng.2983

Oh, S. C. et al. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat. Commun. 9, 1777 (2018).

pubmed: 29725014 pmcid: 5934392 doi: 10.1038/s41467-018-04179-8

Tanaka, Y. et al. Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities. Nat. Cancer 2, 962–977 (2021).

pubmed: 35121863 doi: 10.1038/s43018-021-00240-6

Wang, R. et al. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut 69, 18–31 (2020).

pubmed: 31171626 doi: 10.1136/gutjnl-2018-318070

Bettington, M. et al. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 62, 367–386 (2013).

pubmed: 23339363 doi: 10.1111/his.12055

Zajac, O. et al. Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas. Nat. Cell Biol. 20, 296–306 (2018).

pubmed: 29403038 doi: 10.1038/s41556-017-0027-6

Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015).

pubmed: 26457759 pmcid: 4636487 doi: 10.1038/nm.3967

Ubink, I. et al. Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. Br. J. Surg. 105, e204–e211 (2018).

pubmed: 29341165 doi: 10.1002/bjs.10788

Heinemann, V., Stintzing, S., Kirchner, T., Boeck, S. & Jung, A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat. Rev. 35, 262–271 (2009).

pubmed: 19117687 doi: 10.1016/j.ctrv.2008.11.005

Deng, G. et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin. Cancer Res. 10, 191–195 (2004).

pubmed: 14734469 doi: 10.1158/1078-0432.CCR-1118-3

Arjona-Sanchez, A. et al. RAS mutation decreases overall survival after optimal cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of colorectal peritoneal metastasis: a modification proposal of the peritoneal surface disease severity score. Ann. Surg. Oncol. 26, 2595–2604 (2019).

pubmed: 31111351 doi: 10.1245/s10434-019-07378-9

Schneider, M. A. et al. Mutations of RAS/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann. Surg. 268, 845–853 (2018).

pubmed: 30303876 doi: 10.1097/SLA.0000000000002899

Cohen, R., Pudlarz, T., Delattre, J.-F., Colle, R. & Andre, T. Molecular targets for the treatment of metastatic colorectal cancer. Cancers 12, 2350 (2020).

pmcid: 7563268 doi: 10.3390/cancers12092350

Pietrantonio, F. et al. ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer. J. Natl Cancer Inst. 109, djx089 (2017).

doi: 10.1093/jnci/djx089

André, T. et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N. Engl. J. Med. 383, 2207–2218 (2020).

pubmed: 33264544 doi: 10.1056/NEJMoa2017699

Sallum, L. F. et al. WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosis. Oncotarget 9, 15818–15827 (2018).

pubmed: 29662608 pmcid: 5882299 doi: 10.18632/oncotarget.24530

Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495–2505 (2018).

pubmed: 30345884 doi: 10.1056/NEJMoa1810858

Miller, R. E. et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann. Oncol. 31, 1606–1622 (2020).

pubmed: 33004253 doi: 10.1016/j.annonc.2020.08.2102

Chiang, Y.-C., Lin, P.-H. & Cheng, W.-F. Homologous recombination deficiency assays in epithelial ovarian cancer: current status and future direction. Front. Oncol. 11, 675972 (2021).

pubmed: 34722237 pmcid: 8551835 doi: 10.3389/fonc.2021.675972

Ubink, I. et al. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy. Br. J. Surg. 106, 1404–1414 (2019).

pubmed: 31197820 pmcid: 6771632 doi: 10.1002/bjs.11206

Narasimhan, V. et al. Medium-throughput drug screening of patient-derived organoids from colorectal peritoneal metastases to direct personalized therapy. Clin. Cancer Res. 26, 3662–3670 (2020).

pubmed: 32376656 pmcid: 8366292 doi: 10.1158/1078-0432.CCR-20-0073

Votanopoulos, K. I. et al. Appendiceal cancer patient-specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment: a feasibility study. Ann. Surg. Oncol. 26, 139–147 (2019).

pubmed: 30414038 doi: 10.1245/s10434-018-7008-2

Letai, A. Functional precision cancer medicine — moving beyond pure genomics. Nat. Med. 23, 1028–1035 (2017).

pubmed: 28886003 doi: 10.1038/nm.4389

Roy, P. et al. Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: preclinical models to improve HIPEC. Int. J. Pharm. 531, 143–152 (2017).

pubmed: 28803938 doi: 10.1016/j.ijpharm.2017.07.084

Mazzocchi, A. R., Rajan, S. A. P., Votanopoulos, K. I., Hall, A. R. & Skardal, A. In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening. Sci. Rep. 8, 2886 (2018).

pubmed: 29440675 pmcid: 5811529 doi: 10.1038/s41598-018-21200-8

Votanopoulos, K. I. et al. Model of patient-specific immune-enhanced organoids for immunotherapy screening: feasibility study. Ann. Surg. Oncol. 27, 1956–1967 (2020).

pubmed: 31858299 doi: 10.1245/s10434-019-08143-8

Dhanisha, S. S., Guruvayoorappan, C., Drishya, S. & Abeesh, P. Mucins: structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets. Crit. Rev. Oncol. Hematol. 122, 98–122 (2018).

pubmed: 29458795 doi: 10.1016/j.critrevonc.2017.12.006

Rhodes, J. M. Usefulness of novel tumour markers. Ann. Oncol. 10, S118–S121 (1999).

doi: 10.1093/annonc/10.suppl_4.S118

Young, R. H. Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms. Semin. Diagn. Pathol. 21, 134–150 (2004).

pubmed: 15807473 doi: 10.1053/j.semdp.2004.12.002

O’Connell, J. T., Tomlinson, J. S., Roberts, A. A., McGonigle, K. F. & Barsky, S. H. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am. J. Pathol. 161, 551–564 (2002).

pubmed: 12163380 pmcid: 1850719 doi: 10.1016/S0002-9440(10)64211-3

Lohani, K. et al. Pseudomyxoma peritonei: inflammatory responses in the peritoneal microenvironment. Ann. Surg. Oncol. 21, 1441–1447 (2014).

pubmed: 24046117 doi: 10.1245/s10434-013-3261-6

O’Connell, J. T., Hacker, C. M. & Barsky, S. H. MUC2 is a molecular marker for pseudomyxoma peritonei. Mod. Pathol. 15, 958–972 (2002).

pubmed: 12218214 doi: 10.1097/01.MP.0000026617.52466.9F

Amini, A., Masoumi-Moghaddam, S., Ehteda, A. & Morris, D. L. Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects. Orphanet J. Rare Dis. 9, 71 (2014).

pubmed: 24886459 pmcid: 4013295 doi: 10.1186/1750-1172-9-71

Huang, Y. et al. Intraoperative macroscopic tumour consistency is associated with overall survival after cytoreductive surgery and intraperitoneal chemotherapy for appendiceal adenocarcinoma with peritoneal metastases: a retrospective observational study. Am. J. Surg. 217, 704–712 (2019).

pubmed: 30704669 doi: 10.1016/j.amjsurg.2018.12.037

Nagtegaal, I. D. et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 76, 182–188 (2020).

pubmed: 31433515 doi: 10.1111/his.13975

Benesch, M. G. K. & Mathieson, A. Epidemiology of signet ring cell adenocarcinomas. Cancers 12, 1544 (2020).

pmcid: 7352645 doi: 10.3390/cancers12061544

Berger, Y. et al. Correlation between intraoperative and pathological findings for patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann. Surg. Oncol. 26, 1103–1109 (2019).

pubmed: 30746598 doi: 10.1245/s10434-019-07219-9

Bhatt, A. et al. The pathologic peritoneal cancer index (PCI) strongly differs from the surgical PCI in peritoneal metastases arising from various primary tumors. Ann. Surg. Oncol. 10, 3–12 (2020).

Sessa, C. et al. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann. Oncol. 30, 672–705 (2019).

pubmed: 31046081 doi: 10.1093/annonc/mdz062

Bois, Adu et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115, 1234–1244 (2009).

pubmed: 19189349 doi: 10.1002/cncr.24149

Harter, P. et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N. Engl. J. Med. 385, 2123–2131 (2021).

pubmed: 34874631 doi: 10.1056/NEJMoa2103294

Quenet, F. et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 22, 256–266 (2021).

pubmed: 33476595 doi: 10.1016/S1470-2045(20)30599-4

Franko, J. et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol. 17, 1709–1719 (2016).

pubmed: 27743922 doi: 10.1016/S1470-2045(16)30500-9

Elias, D. et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J. Clin. Oncol. 27, 681–685 (2009).

pubmed: 19103728 doi: 10.1200/JCO.2008.19.7160

Chua, T. C. et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J. Clin. Oncol. 30, 2449–2456 (2012).

pubmed: 22614976 doi: 10.1200/JCO.2011.39.7166

Yan, T. D. et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J. Clin. Oncol. 27, 6237–6242 (2009).

pubmed: 19917862 doi: 10.1200/JCO.2009.23.9640

Govaerts, K. et al. Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Eur. J. Surg. Oncol. 47, 11–35 (2021).

pubmed: 32199769 doi: 10.1016/j.ejso.2020.02.012

Kusamura, S. et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur. J. Surg. Oncol. 47, 36–59 (2021).

pubmed: 32209311 doi: 10.1016/j.ejso.2020.02.011

Ansari, N. et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur. J. Surg. Oncol. 42, 1035–1041 (2016).

pubmed: 27132072 doi: 10.1016/j.ejso.2016.03.017

Chia, C. S. et al. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann. Surg. Oncol. 23, 1971–1979 (2016).

pubmed: 26753751 doi: 10.1245/s10434-015-5081-3

Brandl, A., Yonemura, Y., Glehen, O., Sugarbaker, P. & Rau, B. Long term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: a multi-institutional cohort from PSOGI. Eur. J. Surg. Oncol. 47, 172–180 (2021).

pubmed: 33071173 doi: 10.1016/j.ejso.2020.10.006

Bonnot, P.-E. et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J. Clin. Oncol. 37, 2028–2040 (2019).

pubmed: 31084544 doi: 10.1200/JCO.18.01688

Bonnot, P. E. et al. Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study). Br. J. Surg. 108, 1225–1235 (2021).

pubmed: 34498666 doi: 10.1093/bjs/znab200

Kusamura, S. et al. Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei. Br. J. Surg. 101, 1758–1765 (2014).

pubmed: 25329419 doi: 10.1002/bjs.9674

Passot, G. et al. A perioperative clinical pathway can dramatically reduce failure-to-rescue rates after cytoreductive surgery for peritoneal carcinomatosis: a retrospective study of 666 consecutive cytoreductions. Ann. Surg. 265, 806–813 (2017).

pubmed: 27775553 doi: 10.1097/SLA.0000000000001723

Noiret, B. et al. Centralization and oncologic training reduce postoperative morbidity and failure-to-rescue rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: study on a 10-year national french practice. Ann. Surg. 272, 847–854 (2020).

pubmed: 32833761 doi: 10.1097/SLA.0000000000004326

Stang, N. L. et al. Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: a population-based study. Cancer Epidemiol. 60, 106–111 (2019).

pubmed: 30953970 doi: 10.1016/j.canep.2019.03.014

Villeneuve, L. et al. The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry. Orphanet J. Rare Dis. 12, 37–39 (2017).

pubmed: 28212684 pmcid: 5316145 doi: 10.1186/s13023-017-0571-y

Cavaliere, F. et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur. J. Surg. Oncol. 37, 148–154 (2011).

pubmed: 21093205 doi: 10.1016/j.ejso.2010.10.014

Manzanedo, I. et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Ann. Surg. Oncol. 26, 2615–2621 (2019).

pubmed: 31115852 doi: 10.1245/s10434-019-07450-4

Arjona-Sánchez, Á. et al. A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC) in limited peritoneal carcinomatosis: the American society of peritoneal surface malignancies (ASPSM) multi-institution analysis. Surg. Endosc. 33, 854–860 (2018).

pubmed: 30003349 doi: 10.1007/s00464-018-6352-4

Kusamura, S. et al. Learning curve, training program, and monitorization of surgical performance of peritoneal surface malignancies centers. Surg. Oncol. Clin. N. Am. 27, 507–517 (2018).

pubmed: 29935686 doi: 10.1016/j.soc.2018.02.009

Reuss, A. et al. TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). Int. J. Gynecol. Cancer 29, 1327 (2019).

pubmed: 31420412 doi: 10.1136/ijgc-2019-000682

Mariani, A. et al. Strategies for managing intraoperative discovery of limited colorectal peritoneal metastases. Ann. Surg. Oncol. 26, 1437–1444 (2019).

pubmed: 30805806 doi: 10.1245/s10434-019-07225-x

Faron, M. et al. Linear relationship of peritoneal cancer index and survival in patients with peritoneal metastases from colorectal cancer. Ann. Surg. Oncol. 23, 114–119 (2016).

pubmed: 26014158 doi: 10.1245/s10434-015-4627-8

Goéré, D. et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann. Surg. Oncol. 22, 2958–2964 (2015).

pubmed: 25631064 doi: 10.1245/s10434-015-4387-5

van’t Sant, I. et al. Diagnostic performance of imaging for the detection of peritoneal metastases: a meta-analysis. Eur. Radiol. 30, 3101–3112 (2020).

doi: 10.1007/s00330-019-06524-x

Mohkam, K. et al. Resectability of peritoneal carcinomatosis: learnings from a prospective cohort of 533 consecutive patients selected for cytoreductive surgery. Ann. Surg. Oncol. 23, 1261–1270 (2016).

pubmed: 26628435 doi: 10.1245/s10434-015-5005-2

Sugarbaker, P. H. & Low, R. N. (eds) Pictorial Essays On Peritoneal Metastases Imaging: CT, MRI and PET-CT (Nova Science Publishers, 2020).

Low, R. N., Barone, R. M. & Rousset, P. Peritoneal MRI in patients undergoing cytoreductive surgery and HIPEC: history, clinical applications, and implementation. Eur. J. Surg. Oncol. 47, 65–74 (2021).

pubmed: 30852063 doi: 10.1016/j.ejso.2019.02.030

Dohan, A. et al. Evaluation of the peritoneal carcinomatosis index with CT and MRI. Br. J. Surg. 104, 1244–1249 (2017).

pubmed: 28376270 doi: 10.1002/bjs.10527

Sant, I. V. T. et al. Diffusion-weighted MRI assessment of the peritoneal cancer index before cytoreductive surgery. Br. J. Surg. 106, 491–498 (2019).

doi: 10.1002/bjs.10989

Delhorme, J.-B. et al. Appendiceal tumors and pseudomyxoma peritonei: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). Dig. Liver Dis. 54, 30–39 (2022).

pubmed: 34815194 doi: 10.1016/j.dld.2021.10.005

Menassel, B. et al. Preoperative CT and MRI prediction of non-resectability in patients treated for pseudomyxoma peritonei from mucinous appendiceal neoplasms. Eur. J. Surg. Oncol. 42, 558–566 (2016).

pubmed: 26856956 doi: 10.1016/j.ejso.2016.01.005

Lehmann, K. et al.

pubmed: 27692533 doi: 10.1016/j.ejso.2016.08.020

Kim, S.-J. & Lee, S.-W. Diagnostic accuracy of

pubmed: 29099613 doi: 10.1259/bjr.20170519

Sugarbaker, P. H. et al. Concerning CT features used to select patients for treatment of peritoneal metastases, a pictoral essay. Int. J. Hyperthermia 33, 497–504 (2017).

pubmed: 28540832 doi: 10.1080/02656736.2017.1317368

Chandramohan, A. et al. Communicating imaging findings in peritoneal mesothelioma: the impact of ‘PAUSE’ on surgical decision-making. Insights Imaging 12, 174 (2021).

pubmed: 34817720 pmcid: 8613330 doi: 10.1186/s13244-021-01118-y

Chandramohan, A., Thrower, A., Smith, S. A., Shah, N. & Moran, B. “PAUSE”: a method for communicating radiological extent of peritoneal malignancy. Clin. Radiol. 72, 972–980 (2017).

pubmed: 28778454 doi: 10.1016/j.crad.2017.07.005

Lennartz, S. et al. Iodine overlays to improve differentiation between peritoneal carcinomatosis and benign peritoneal lesions. Eur. Radiol. 30, 3968–3976 (2020).

pubmed: 32125516 doi: 10.1007/s00330-020-06729-5

Darras, K. E. et al. Virtual monoenergetic reconstruction of contrast-enhanced CT scans of the abdomen and pelvis at 40 keV improves the detection of peritoneal metastatic deposits. Abdom. Radiol. 44, 422–428 (2019).

doi: 10.1007/s00261-018-1733-7

Thivolet, A. et al. Spectral photon-counting CT imaging of colorectal peritoneal metastases: initial experience in rats. Sci. Rep. 10, 13394 (2020).

pubmed: 32770125 pmcid: 7414131 doi: 10.1038/s41598-020-70282-w

Zhao, L. et al. Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [

doi: 10.1007/s00259-020-05146-6

Kuten, J. et al. Head-to-head comparison of [

pubmed: 34302504 doi: 10.1007/s00259-021-05494-x

van’t Sant, I. et al. Seeing the whole picture: added value of MRI for extraperitoneal findings in CRS-HIPEC candidates. Eur. J. Surg. Oncol. 48, 462–469 (2022).

doi: 10.1016/j.ejso.2021.09.014

Wang, W. et al. Are positron emission tomography-computed tomography (PET-CT) scans useful in preoperative assessment of patients with peritoneal disease before cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)? Int. J. Hyperthermia 34, 524–531 (2018).

pubmed: 28854825 doi: 10.1080/02656736.2017.1366554

Vuysere, S. D. et al. Accuracy of whole-body diffusion-weighted MRI (WB-DWI/MRI) in diagnosis, staging and follow-up of gastric cancer, in comparison to CT: a pilot study. BMC Med. Imaging 21, 18 (2021).

pubmed: 33546626 pmcid: 7866710 doi: 10.1186/s12880-021-00550-2

Dresen, R. C. et al. Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases. Cancer Imaging 19, 1 (2019).

pubmed: 30616608 pmcid: 6322317 doi: 10.1186/s40644-018-0187-z

Brendle, C. et al. Assessment of metastatic colorectal cancer with hybrid imaging: comparison of reading performance using different combinations of anatomical and functional imaging techniques in PET/MRI and PET/CT in a short case series. Eur. J. Nucl. Med. Mol. I 43, 123–132 (2016).

doi: 10.1007/s00259-015-3137-z

Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).

pubmed: 19097774 doi: 10.1016/j.ejca.2008.10.026

Bhatt, A. et al. Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumours treated by cytoreductive surgery: study protocol of a prospective, multicentre, observational study. BMJ Open 11, e046819 (2021).

pubmed: 34226220 pmcid: 8258594 doi: 10.1136/bmjopen-2020-046819

Bhatt, A. et al. Clinical and radiologic predictors of a pathologic complete response to neoadjuvant chemotherapy (NACT) in patients undergoing cytoreductive surgery for colorectal peritoneal metastases: results of a prospective multi-center study. Ann. Surg. Oncol. 28, 3840–3849 (2021).

pubmed: 33210270 doi: 10.1245/s10434-020-09330-8

Liberale, G. et al. Accuracy of FDG-PET/CT in colorectal peritoneal carcinomatosis: potential tool for evaluation of chemotherapeutic response. Anticancer Res. 37, 929–934 (2017).

pubmed: 28179354 doi: 10.21873/anticanres.11401

Park, S. J. et al. Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial. BMC Cancer 20, 385 (2020).

pubmed: 32375688 pmcid: 7201947 doi: 10.1186/s12885-020-06886-2

Sala, E. et al. Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects. Radiology 263, 149–159 (2012).

pubmed: 22332064 doi: 10.1148/radiol.11110175

Himoto, Y. et al. Computed tomography–derived radiomic metrics can identify responders to immunotherapy in ovarian cancer. JCO Precis. Oncol. 3, 1–13 (2019).

Nougaret, S. et al. Radiomics and radiogenomics in ovarian cancer: a literature review. Abdom. Radiol. 46, 2308–2322 (2021).

doi: 10.1007/s00261-020-02820-z

Mikkelsen, M. S. et al. Assessment of peritoneal metastases with DW-MRI, CT, and FDG PET/CT before cytoreductive surgery for advanced stage epithelial ovarian cancer. Eur. J. Surg. Oncol. 47, 2134–2141 (2021).

pubmed: 33812768 doi: 10.1016/j.ejso.2021.03.239

Engbersen, M. P. et al. Dedicated MRI staging versus surgical staging of peritoneal metastases in colorectal cancer patients considered for CRS-HIPEC; the DISCO randomized multicenter trial. BMC Cancer 21, 464 (2021).

pubmed: 33902498 pmcid: 8077799 doi: 10.1186/s12885-021-08168-x

Passot, G. et al. Multicentre study of laparoscopic or open assessment of the peritoneal cancer index (BIG-RENAPE). Br. J. Surg. 105, 663–667 (2018).

pubmed: 29579322 doi: 10.1002/bjs.10723

Iversen, L. H., Rasmussen, P. C. & Laurberg, S. Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Br. J. Surg. 100, 285–292 (2013).

pubmed: 23124619 doi: 10.1002/bjs.8908

Sell, N. M. et al. Staging laparoscopy not only saves patients an incision, but may also help them live longer. Ann. Surg. Oncol. 25, 1009–1016 (2018).

pubmed: 29388123 doi: 10.1245/s10434-017-6317-1

Allen, C. J. et al. Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer. J. Surg. Oncol. 120, 1350–1357 (2019).

pubmed: 31612494 doi: 10.1002/jso.25729

Blackshaw, G. R. J. C. et al. Laparoscopy significantly improves the perceived preoperative stage of gastric cancer. Gastric Cancer 6, 225–229 (2003).

pubmed: 14716516 doi: 10.1007/s10120-003-0257-0

Sarela, A. I., Lefkowitz, R., Brennan, M. F. & Karpeh, M. S. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am. J. Surg. 191, 134–138 (2006).

pubmed: 16399124 doi: 10.1016/j.amjsurg.2005.10.015

Passot, G. et al. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies. Eur. J. Surg. Oncol. 40, 957–962 (2014).

pubmed: 24209429 doi: 10.1016/j.ejso.2013.10.002

Dong, D. et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. Ann. Oncol. 30, 431–438 (2019).

pubmed: 30689702 pmcid: 6442651 doi: 10.1093/annonc/mdz001

Jiang, Y. et al. Predicting peritoneal recurrence and disease-free survival from CT images in gastric cancer with multitask deep learning: a retrospective study. Lancet Digital Heal. 4, e340–e350 (2022).

doi: 10.1016/S2589-7500(22)00040-1

Passot, G. et al. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann. Surg. Oncol. 21, 2608–2614 (2014).

pubmed: 24668148 doi: 10.1245/s10434-014-3647-0

Goere, D. et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 21, 1147–1154 (2020).

pubmed: 32717180 doi: 10.1016/S1470-2045(20)30322-3

Bhatt, A. et al. Prospective correlation of the radiological, surgical and pathological findings in patients undergoing cytoreductive surgery for colorectal peritoneal metastases: implications for the preoperative estimation of the peritoneal cancer index. Colorectal Dis. 22, 2123–2132 (2020).

pubmed: 32940414 doi: 10.1111/codi.15368

Bhatt, A. & Glehen, O. Extent of peritoneal resection for peritoneal metastases: looking beyond a complete cytoreduction. Ann. Surg. Oncol. 27, 1458–1470 (2020).

pubmed: 31965374 doi: 10.1245/s10434-020-08208-z

Veys, I. et al. ICG-fluorescence imaging for detection of peritoneal metastases and residual tumoral scars in locally advanced ovarian cancer: a pilot study. J. Surg. Oncol. 117, 228–235 (2018).

pubmed: 28787759 doi: 10.1002/jso.24807

Zapardiel, I. et al. Utility of intraoperative fluorescence imaging in gynecologic surgery: systematic review and consensus statement. Ann. Surg. Oncol. 28, 3266–3278 (2021).

pubmed: 33095359 doi: 10.1245/s10434-020-09222-x

Bhatt, A. & Glehen, O. ASO author reflections: tailoring the extent of peritoneal resection for peritoneal metastases according to the primary tumor site. Ann. Surg. Oncol. 27, 1471–1472 (2020).

pubmed: 32162077 doi: 10.1245/s10434-020-08344-6

Baratti, D., Kusamura, S., Cabras, A. D. & Deraco, M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann. Surg. Oncol. 19, 1416–1424 (2012).

pubmed: 22302266 doi: 10.1245/s10434-012-2237-2

Bhatt, A. et al. Total parietal peritonectomy can be performed with acceptable morbidity for patients with advanced ovarian cancer after neoadjuvant chemotherapy: results from a prospective multi-centric study. Ann. Surg. Oncol. 28, 1118–1129 (2021).

pubmed: 32748154 doi: 10.1245/s10434-020-08918-4

Sinukumar, S. et al. A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer–a study by INDEPSO. Eur. J. Surg. Oncol. 47, 75–81 (2021).

pubmed: 30857879 doi: 10.1016/j.ejso.2019.02.031

Lawrence, V. A. et al. Functional independence after major abdominal surgery in the elderly. J. Am. Coll. Surg. 199, 762–772 (2004).

pubmed: 15501119 doi: 10.1016/j.jamcollsurg.2004.05.280

Christensen, T. & Kehlet, H. Postoperative fatigue. World J. Surg. 17, 220–225 (1993).

pubmed: 8511917 doi: 10.1007/BF01658930

Baratti, D. et al. Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients. Dis. Colon Rectum 57, 858–868 (2014).

pubmed: 24901687 doi: 10.1097/DCR.0000000000000149

Ditmyer, M. M., Topp, R. & Pifer, M. Prehabilitation in preparation for orthopaedic surgery. Orthop. Nurs. 21, 43–54 (2002).

pubmed: 12432699 doi: 10.1097/00006416-200209000-00008

Hübner, M. et al. Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS®) Society Recommendations — Part I: preoperative and intraoperative management. Eur. J. Surg. Oncol. 46, 2292–2310 (2020).

pubmed: 32873454 doi: 10.1016/j.ejso.2020.07.041

Hübner, M. et al. Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS®) society recommendations–Part II: postoperative management and special considerations. Eur. J. Surg. Oncol. 46, 2311–2323 (2020).

pubmed: 32826114 doi: 10.1016/j.ejso.2020.08.006

Dhiman, A. et al. Guide to enhanced recovery for cancer patients undergoing surgery: ERAS for patients undergoing cytoreductive surgery with or without HIPEC. Ann. Surg. Oncol. 28, 6955–6964 (2021).

pubmed: 33954868 doi: 10.1245/s10434-021-09973-1

Vashi, P. G. et al. The relationship between baseline nutritional status with subsequent parenteral nutrition and clinical outcomes in cancer patients undergoing hyperthermic intraperitoneal chemotherapy. Nutr. J. 12, 118–118 (2013).

pubmed: 23941331 pmcid: 3751179 doi: 10.1186/1475-2891-12-118

Mills, E. et al. Smoking cessation reduces postoperative complications: a systematic review and meta-analysis. Am. J. Med. 124, 144–154.e8 (2011).

pubmed: 21295194 doi: 10.1016/j.amjmed.2010.09.013

Thomsen, T., Villebro, N. & Møller, A. M. Interventions for preoperative smoking cessation. Cochrane Database Syst. Rev. 3, CD002294 (2014).

Iqbal, U. et al. Preoperative patient preparation in enhanced recovery pathways. J. Anaesthesiol. Clin. Pharmacol. 35, S14–S23 (2019).

pubmed: 31142954 pmcid: 6515717 doi: 10.4103/joacp.JOACP_54_18

Pouwels, S. et al. Preoperative exercise therapy for elective major abdominal surgery: a systematic review. Int. J. Surg. 12, 134–140 (2014).

pubmed: 24325942 doi: 10.1016/j.ijsu.2013.11.018

Boukili, I. E. et al. Prehabilitation before major abdominal surgery: evaluation of the impact of a perioperative clinical pathway, a pilot study. Scand. J. Surg. 111, 145749692210833 (2022).

doi: 10.1177/14574969221083394

Alyami, M. et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly: a case-controlled, multicenter study. Ann. Surg. Oncol. 23, 737–745 (2016).

pubmed: 27600619 doi: 10.1245/s10434-016-5519-2

Dion, L. et al. Ovarian cancer in the elderly: time to move towards a more logical approach to improve prognosis — a study from the FRANCOGYN Group. J. Clin. Med. 9, 1339 (2020).

pmcid: 7291201 doi: 10.3390/jcm9051339

Gagniere, J. et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the elderly: is it reasonable? a meta-analysis. Ann. Surg. Oncol. 25, 709–719 (2018).

pubmed: 29282602 doi: 10.1245/s10434-017-6313-5

Rubenstein, L. Z., Stuck, A. E., Siu, A. L. & Wieland, D. Impacts of geriatric evaluation and management programs on defined outcomes: overview of the evidence. J. Am. Geriatr. Soc. 39, 8S–16S (1991).

pubmed: 1832179 doi: 10.1111/j.1532-5415.1991.tb05927.x

Soubeyran, P. et al. Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study. PLoS ONE 9, e115060 (2014).

pubmed: 25503576 pmcid: 4263738 doi: 10.1371/journal.pone.0115060

Hamaker, M. E. et al. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol. 13, e437–e444 (2012).

pubmed: 23026829 doi: 10.1016/S1470-2045(12)70259-0

Wildiers, H. et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J. Clin. Oncol. 32, 2595–2603 (2014).

pubmed: 25071125 pmcid: 4876338 doi: 10.1200/JCO.2013.54.8347

Mohanty, S. et al. Optimal perioperative management of the geriatric patient: a best practices guideline from the american college of surgeons NSQIP and the American Geriatrics Society. J. Am. Coll. Surg. 222, 930–947 (2016).

pubmed: 27049783 doi: 10.1016/j.jamcollsurg.2015.12.026

Minnella, E. M. et al. Patients with poor baseline walking capacity are most likely to improve their functional status with multimodal prehabilitation. Surgery 160, 1070–1079 (2016).

pubmed: 27476586 doi: 10.1016/j.surg.2016.05.036

Roche, M. et al. Feasibility of a prehabilitation programme dedicated to older patients with cancer before complex medical–surgical procedures: the PROADAPT pilot study protocol. BMJ Open 11, e042960 (2021).

pubmed: 33811052 pmcid: 8023742 doi: 10.1136/bmjopen-2020-042960

Falandry, C. et al. Interventions to improve physical performances of older people with cancer before complex medico-surgical procedures. Medicine 99, e21780 (2020).

pubmed: 32991400 pmcid: 7523808 doi: 10.1097/MD.0000000000021780

Cederholm, T. et al. GLIM criteria for the diagnosis of malnutrition – a consensus report from the global clinical nutrition community. Clin. Nutr. 38, 1–9 (2019).

pubmed: 30181091 doi: 10.1016/j.clnu.2018.08.002

Boereboom, C., Doleman, B., Lund, J. N. & Williams, J. P. Systematic review of pre-operative exercise in colorectal cancer patients. Tech. Coloproctol. 20, 81–89 (2016).

pubmed: 26614304 doi: 10.1007/s10151-015-1407-1

Launay-Savary, M.-V. et al. Are enhanced recovery programs in colorectal surgery feasible and useful in the elderly? A systematic review of the literature. J. Visc. Surg. 154, 29–35 (2017).

pubmed: 27842907 doi: 10.1016/j.jviscsurg.2016.09.016

Dedrick, R. L. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin. Oncol. 12 (3 Suppl. 4), 1–6 (1985).

pubmed: 4048968

Dedrick, R. L., Myers, C. E., Bungay, P. M. & DeVita, V. T. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62, 1–11 (1978).

pubmed: 626987

Ceelen, W. P. & Flessner, M. F. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat. Rev. Clin. Oncol. 7, 108–115 (2010).

pubmed: 20010898 doi: 10.1038/nrclinonc.2009.217

Nagy, J. A., Chang, S.-H., Shih, S.-C., Dvorak, A. M. & Dvorak, H. F. Heterogeneity of the tumor vasculature. Semin. Thromb. Hemost. 36, 321–331 (2010).

pubmed: 20490982 pmcid: 3278036 doi: 10.1055/s-0030-1253454

Heldin, C.-H., Rubin, K., Pietras, K. & Östman, A. High interstitial fluid pressure – an obstacle in cancer therapy. Nat. Rev. Cancer 4, 806–813 (2004).

pubmed: 15510161 doi: 10.1038/nrc1456

Spratt, J. S., Adcock, R. A., Muskovin, M., Sherrill, W. & McKeown, J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 40, 256–260 (1980).

pubmed: 6766084

Issels, R. D. Hyperthermia adds to chemotherapy. Eur. J. Cancer 44, 2546–2554 (2008).

pubmed: 18789678 doi: 10.1016/j.ejca.2008.07.038

Reymond, M. A. et al. Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator. Surg. Endosc. 14, 51–55 (2000).

pubmed: 10653236 doi: 10.1007/s004649900010

Reis, A. C. V. et al. Hemodynamic and respiratory implications of high intra-abdominal pressure during HIPEC. Eur. J. surg. Oncol. 46, 1896–1901 (2020).

pubmed: 32147425 doi: 10.1016/j.ejso.2020.02.006

Sugarbaker, P. H. & Jablonski, K. A. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann. Surg. 221, 124–132 (1995).

pubmed: 7857141 pmcid: 1234945 doi: 10.1097/00000658-199502000-00002

der Speeten, K. V. & Lemoine, L. In Management of Peritoneal Metastases: Cytoreductive Surgery, HIPEC and Beyond (ed. Bhatt A.) 79–102 (Springer, 2017).

Urano, M., Kuroda, M. & Nishimura, Y. For the clinical application of thermochemotherapy given at mild temperatures. Int. J. Hyperthermia 15, 79–107 (1999).

pubmed: 10323618 doi: 10.1080/026567399285765

Leunig, M. et al. Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res. 52, 487–490 (1992).

pubmed: 1728421

Hettinga, J. et al. Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells. Br. J. Cancer 75, 1735–1743 (1997).

pubmed: 9192975 pmcid: 2223603 doi: 10.1038/bjc.1997.297

Hettinga, J. V., Konings, A. W. & Kampinga, H. H. Reduction of cellular cisplatin resistance by hyperthermia-a review. Int. J. Hyperthermia 13, 439–457 (1997).

pubmed: 9354931 doi: 10.3109/02656739709023545

Wallner, K. E. & Li, G. C. Effect of drug exposure duration and sequencing on hyperthermic potentiation of mitomycin-C and cisplatin. Cancer Res. 47, 493–495 (1987).

pubmed: 3098412

Yurttas, C. et al. Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer. J. Clin. Med. 7, 567 (2018).

pmcid: 6306814 doi: 10.3390/jcm7120567

Bhatt, A. et al. HIPEC methodology and regimens: the need for an expert consensus. Ann. Surg. Oncol. 28, 9098–9113 (2021).

pubmed: 34142293 doi: 10.1245/s10434-021-10193-w

Driel, W. Jvan et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N. Engl. J. Med. 378, 230–240 (2018).

pubmed: 29342393 doi: 10.1056/NEJMoa1708618

Yang, X.-J. et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase iii randomized clinical trial. Ann. Surg. Oncol. 18, 1575–1581 (2011).

pubmed: 21431408 pmcid: 3087875 doi: 10.1245/s10434-011-1631-5

Park, E. J. et al. Pharmacologic properties of the carrier solutions for hyperthermic intraperitoneal chemotherapy: comparative analyses between water and lipid carrier solutions in the rat model. Ann. Surg. Oncol. 25, 3185–3192 (2018).

pubmed: 30027459 pmcid: 6132421 doi: 10.1245/s10434-018-6628-x

Piché, N. et al. Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model. Ann. Surg. 254, 138–144 (2011).

pubmed: 21494122 doi: 10.1097/SLA.0b013e3182193143

Bespalov, V. G. et al. Comparative efficacy evaluation of catheter intraperitoneal chemotherapy, normothermic and hyperthermic chemoperfusion in a rat model of ascitic ovarian cancer. Int. J. Hyperthermia 34, 545–550 (2017).

pubmed: 28893108 doi: 10.1080/02656736.2017.1375161

Raue, W. et al. Multimodal approach for treatment of peritoneal surface malignancies in a tumour-bearing rat model. Int. J. Colorectal Dis. 25, 245–250 (2010).

pubmed: 19902227 doi: 10.1007/s00384-009-0819-7

Ortega-Deballon, P. et al. Which method to deliver hyperthermic intraperitoneal chemotherapy with oxaliplatin? An experimental comparison of open and closed techniques. Ann. Surg. Oncol. 17, 1957–1963 (2010).

pubmed: 20143265 doi: 10.1245/s10434-010-0937-z

Helderman, R. F. C. P. A. et al. Preclinical in vivo-models to investigate HIPEC; current methodologies and challenges. Cancers 13, 3430 (2021).

pubmed: 34298644 pmcid: 8303745 doi: 10.3390/cancers13143430

Lemoine, L. et al. Body surface area-based versus concentration-based intraperitoneal perioperative chemotherapy in a rat model of colorectal peritoneal surface malignancy: pharmacologic guidance towards standardization. Oncotarget 10, 1407–1424 (2019).

pubmed: 30858926 pmcid: 6402719 doi: 10.18632/oncotarget.26667

Löffler, M. W. et al. Pharmacodynamics of oxaliplatin-derived platinum compounds during hyperthermic intraperitoneal chemotherapy (HIPEC): an emerging aspect supporting the rational design of treatment protocols. Ann. Surg. Oncol. 24, 1650–1657 (2017).

pubmed: 28160138 doi: 10.1245/s10434-017-5790-x

Elekonawo, F. M. K. et al. Effect of intraperitoneal chemotherapy concentration on morbidity and survival. BJS Open 4, 293–300 (2020).

pubmed: 31950702 pmcid: 7093784 doi: 10.1002/bjs5.50250

Löke, D. R. et al. Simulating drug penetration during hyperthermic intraperitoneal chemotherapy. Drug Deliv. 28, 145–161 (2021).

pubmed: 33427507 pmcid: 7808385 doi: 10.1080/10717544.2020.1862364

Prabhu, A. et al. Effect of oxaliplatin-based chemotherapy on chemosensitivity in patients with peritoneal metastasis from colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: proof-of-concept study. BJS Open 5, zraa075 (2021).

pubmed: 33839755 pmcid: 8038512 doi: 10.1093/bjsopen/zraa075

Hübner, M. et al. Pressurized IntraPeritoneal aerosol chemotherapy - practical aspects. Eur. J. Surg. Oncol. 43, 1102–1109 (2017).

pubmed: 28431896 doi: 10.1016/j.ejso.2017.03.019

Alyami, M. et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 20, e368–e377 (2019).

pubmed: 31267971 doi: 10.1016/S1470-2045(19)30318-3

Davigo, A. et al. PIPAC versus HIPEC: cisplatin spatial distribution and diffusion in a swine model. Int. J. Hyperthermia 37, 144–150 (2020).

pubmed: 32003300 doi: 10.1080/02656736.2019.1704891

Solass, W. et al. Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis. Histopathology 74, 1014–1024 (2019).

pubmed: 30687944 doi: 10.1111/his.13829

Solaß, W., Hetzel, A., Nadiradze, G., Sagynaliev, E. and Reymond, M.A. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg. Endosc. 26, 1849–1855 (2012).

pubmed: 22580869 doi: 10.1007/s00464-012-2148-0

Kurtz, F. et al. Feasibility, safety, and efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis: a registry study. Gastroent Res. Pract. 2018, 2743985 (2018).

doi: 10.1155/2018/2743985

Rovers, K. P. et al. Pressurized intraperitoneal aerosol chemotherapy (oxaliplatin) for unresectable colorectal peritoneal metastases: a multicenter, single-arm, phase II trial (CRC-PIPAC). Ann. Surg. Oncol. 28, 5311–5326 (2021).

pubmed: 33544279 doi: 10.1245/s10434-020-09558-4

Tempfer, C. B. et al. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol. Oncol. 150, 23–30 (2018).

pubmed: 29743140 doi: 10.1016/j.ygyno.2018.05.001

Kepenekian, V. et al. Non-resectable malignant peritoneal mesothelioma treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC) plus systemic chemotherapy could lead to secondary complete cytoreductive surgery: a cohort study. Ann. Surg. Oncol. 29, 2104–2113 (2022).

pubmed: 34713369 doi: 10.1245/s10434-021-10983-2

Ellebaek, S. B. et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC)-directed treatment of peritoneal metastasis in end-stage colo-rectal cancer patients. Pleura Peritoneum 5, 20200109 (2020).

pubmed: 32566727 pmcid: 7292236 doi: 10.1515/pp-2020-0109

Alyami, M. et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur. J. Surg. Oncol. 47, 123–127 (2020).

pubmed: 32561204 doi: 10.1016/j.ejso.2020.05.021

Ndaw, S. et al. Occupational exposure to platinum drugs during intraperitoneal chemotherapy. Biomonitoring and surface contamination. Toxicol. Lett. 298, 171–176 (2018).

pubmed: 29852276 doi: 10.1016/j.toxlet.2018.05.031

Clerc, D. et al. Current practice and perceptions of safety protocols for the use of intraperitoneal chemotherapy in the operating room: results of the IP-OR international survey. Pleura Peritoneum 6, 39–45 (2021).

pubmed: 34222648 pmcid: 8223803 doi: 10.1515/pp-2020-0148

Tempfer, C., Giger-Pabst, U., Hilal, Z., Dogan, A. & Rezniczek, G. A. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer. Arch. Gynecol. Obstet. 298, 243–257 (2018).

pubmed: 29869089 doi: 10.1007/s00404-018-4784-7

Hübner, M. et al. Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: technical aspects and treatment protocols. Eur. J. Surg. Oncol. 48, 789–794 (2022).

pubmed: 34785087 doi: 10.1016/j.ejso.2021.10.028

Dumont, F. et al. A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers. Eur. J. Cancer 140, 37–44 (2020).

pubmed: 33039812 doi: 10.1016/j.ejca.2020.09.010

Taibi, A. et al. Feasibility and safety of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy with or without intraoperative intravenous 5-fluorouracil and leucovorin for colorectal peritoneal metastases: a multicenter comparative cohort study. Ann. Surg. Oncol. 29, 5243–5251 (2022).

pubmed: 35318519 doi: 10.1245/s10434-022-11577-2

Sande, L. V. D. et al. Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane

Sgarbura, O. et al. MESOTIP: phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma. Pleura Peritoneum 4, 20190010 (2019).

pubmed: 31417958 pmcid: 6693480 doi: 10.1515/pp-2019-0010

Eveno, C., Jouvin, I. & Pocard, M. PIPAC EstoK 01: pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin (PIPAC C/D) in gastric peritoneal metastasis: a randomized and multicenter phase II study. Pleura Peritoneum 3, 20180116 (2018).

pubmed: 30911659 pmcid: 6405009 doi: 10.1515/pp-2018-0116

Alyami, M. et al. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur. J. Surg. Oncol. 47, 128–133 (2021).

pubmed: 31253545 doi: 10.1016/j.ejso.2019.06.028

Tate, S. J., Sande, L. V., de, Ceelen, W. P., Torkington, J. & Parker, A. L. The feasibility of pressurised intraperitoneal aerosolised virotherapy (PIPAV) to administer oncolytic adenoviruses. Pharm 13, 2043 (2021).

Sugarbaker, P. H., Stuart, O. A., Vidal-Jove, J., Pessagno, A. M. & DeBruijn, E. A. Peritoneal Carcinomatosis: Principles Of Management (Springer, 1996).

Flessner, M. F. The transport barrier in intraperitoneal therapy. Am. J. Physiol. Ren. Physiol. 288, F433–F342 (2005).

doi: 10.1152/ajprenal.00313.2004

Wilson, R. B. Hypoxia, cytokines and stromal recruitment: parallels between pathophysiology of encapsulating peritoneal sclerosis, endometriosis and peritoneal metastasis. Pleura Peritoneum 3, 20180103 (2018).

pubmed: 30911653 pmcid: 6405013 doi: 10.1515/pp-2018-0103

Seebauer, C. T. et al. Peritoneal carcinomatosis of colorectal cancer is characterized by structural and functional reorganization of the tumor microenvironment inducing senescence and proliferation arrest in cancer cells. Oncoimmunology 5, e1242543 (2016).

pubmed: 28439450 pmcid: 5391678 doi: 10.1080/2162402X.2016.1242543

Wang, E. et al. Abundant intratumoral fibrosis prevents lymphocyte infiltration into peritoneal metastases of colorectal cancer. PLoS ONE 16, e0255049 (2021).

pubmed: 34293030 pmcid: 8297902 doi: 10.1371/journal.pone.0255049

Morgan, R. D. et al. Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncol. 22, 277–288 (2021).

pubmed: 33357510 doi: 10.1016/S1470-2045(20)30591-X

Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416–2428 (2019).

pubmed: 31851799 doi: 10.1056/NEJMoa1911361

Coleman, R. L. et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N. Engl. J. Med. 381, 2403–2415 (2019).

pubmed: 31562800 pmcid: 6941439 doi: 10.1056/NEJMoa1909707

Ledermann, J. A. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24, vi24–vi32 (2013).

pubmed: 24078660 doi: 10.1093/annonc/mdt333

Winter-Roach, B. A., Kitchener, H. C. & Dickinson, H. O. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst. Rev. 1, CD004706 (2009).

ICON1. International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J. Natl Cancer Inst. 95, 125–132 (2003).

doi: 10.1093/jnci/95.2.125

McGuire, W. P. et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334, 1–6 (1996).

pubmed: 7494563 doi: 10.1056/NEJM199601043340101

Piccart, M. J. et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl Cancer Inst. 92, 699–708 (2000).

pubmed: 10793106 doi: 10.1093/jnci/92.9.699

Aghajanian, C. et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 30, 2039–2045 (2012).

pubmed: 22529265 pmcid: 3646321 doi: 10.1200/JCO.2012.42.0505

Pujade-Lauraine, E. et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol. 32, 1302–1308 (2014).

pubmed: 24637997 doi: 10.1200/JCO.2013.51.4489

Perren, T. J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484–2496 (2011).

pubmed: 22204725 doi: 10.1056/NEJMoa1103799

Burger, R. A. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473–2483 (2011).

pubmed: 22204724 doi: 10.1056/NEJMoa1104390

Martín, A. G. et al. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecol. Oncol. 152, 53–60 (2019).

doi: 10.1016/j.ygyno.2018.08.036

Monk, B. J. et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 22, 1275–1289 (2021).

pubmed: 34363762 doi: 10.1016/S1470-2045(21)00342-9

Pujade-Lauraine, E. et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 22, 1034–1046 (2021).

pubmed: 34143970 doi: 10.1016/S1470-2045(21)00216-3

Konstantinopoulos, P. A. et al. TOPACIO/Keynote-162 (NCT02657889): a phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC) — results from ROC cohort. J. Clin. Oncol. 36 (suppl. 15), Abstr. 106 (2018).

doi: 10.1200/JCO.2018.36.15_suppl.106

Drew, Y. et al. 1190PD Phase II study of olaparib + durvalumab (MEDIOLA): updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC). Ann. Oncol. 30, v485–v486 (2019).

doi: 10.1093/annonc/mdz253.016

Zsiros, E. et al. Efficacy and safety of pembrolizumab in combination with Bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer. JAMA Oncol. 7, 78–85 (2021).

pubmed: 33211063 doi: 10.1001/jamaoncol.2020.5945

Breuer, E. et al. Site of recurrence and survival after surgery for colorectal peritoneal metastasis. J. Natl Cancer Inst. 113, djab001 (2021).

doi: 10.1093/jnci/djab001

Franko, J. Therapeutic efficacy of systemic therapy for colorectal peritoneal carcinomatosis: surgeon’s perspective. Pleura Peritoneum 3, 20180102 (2018).

pubmed: 30911652 pmcid: 6405010 doi: 10.1515/pp-2018-0102

Cutsem, E. V., Cervantes, A., Nordlinger, B., Arnold, D. & Group, E. G. W. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25, iii1–iii9 (2014).

pubmed: 25190710 doi: 10.1093/annonc/mdu260

Nordlinger, B. et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 14, 1208–1215 (2013).

pubmed: 24120480 doi: 10.1016/S1470-2045(13)70447-9

Loupakis, F. et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N. Engl. J. Med. 371, 1609–1618 (2014).

pubmed: 25337750 doi: 10.1056/NEJMoa1403108

Cremolini, C. et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 21, 497–507 (2020).

pubmed: 32164906 doi: 10.1016/S1470-2045(19)30862-9

Ychou, M. et al. Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial. J. Clin. Oncol. 36 (suppl. 15), Abstr. 3535 (2018).

doi: 10.1200/JCO.2018.36.15_suppl.3535

Rovers, K. et al. LBA-6 Safety, feasibility, tolerability, and preliminary efficacy of perioperative systemic therapy for resectable colorectal peritoneal metastases: pilot phase of a randomised trial (CAIRO6). Ann. Oncol. 31, S243 (2020).

doi: 10.1016/j.annonc.2020.04.081

Rovers, K. P. et al. Perioperative systemic therapy vs cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases. JAMA Surg. 156, 710–720 (2021).

pubmed: 34009291 doi: 10.1001/jamasurg.2021.1642

Rovers, K. P. et al. Adjuvant systemic chemotherapy vs active surveillance following up-front resection of isolated synchronous colorectal peritoneal metastases. JAMA Oncol. 6, e202701 (2020).

pubmed: 32672798 pmcid: 7366283 doi: 10.1001/jamaoncol.2020.2701

Beal, E. W. et al. Impact of neoadjuvant chemotherapy on the outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a multi-institutional retrospective review. J. Clin. Med. 9, 748 (2020).

pmcid: 7141272 doi: 10.3390/jcm9030748

Waite, K. & Youssef, H. The role of neoadjuvant and adjuvant systemic chemotherapy with cytoreductive surgery and heated intraperitoneal chemotherapy for colorectal peritoneal metastases: a systematic review. Ann. Surg. Oncol. 24, 705–720 (2017).

pubmed: 28058545 doi: 10.1245/s10434-016-5712-3

Chau, I. et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J. Clin. Oncol. 22, 2395–2403 (2004).

pubmed: 15197201 doi: 10.1200/JCO.2004.08.154

Kim, J. G. et al. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemoth Pharm. 61, 301–307 (2008).

doi: 10.1007/s00280-007-0476-x

Thomassen, I. et al. Chemotherapy as palliative treatment for peritoneal carcinomatosis of gastric origin. Acta Oncol. 53, 429–432 (2013).

pubmed: 24304392 doi: 10.3109/0284186X.2013.850740

Shitara, K. et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol. Hepatol. 2, 277–287 (2017).

pubmed: 28404157 doi: 10.1016/S2468-1253(16)30219-9

KINOSHITA, J. et al. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer. Oncol. Rep. 32, 89–96 (2014).

pubmed: 24859429 doi: 10.3892/or.2014.3210

Kang, Y.-K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461–2471 (2017).

pubmed: 28993052 doi: 10.1016/S0140-6736(17)31827-5

Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27–40 (2021).

pubmed: 34102137 pmcid: 8436782 doi: 10.1016/S0140-6736(21)00797-2

Shitara, K. et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 6, 1571–1580 (2020).

pubmed: 32880601 doi: 10.1001/jamaoncol.2020.3370

Takahashi, Y. et al. Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08). Gastric Cancer 25, 235–244 (2022).

pubmed: 34427838 doi: 10.1007/s10120-021-01237-x

Goere, D., Glehen, O., Mariette, C., Auperin, A. & Elias, D. Results of a phase II randomized study evaluating the potential benefit of a postoperative intraperitoneal immunotherapy after resection of peritoneal metastases from gastric carcinoma metastases (IIPOP-NCT01784900). J. Clin. Oncol. 35 (suppl. 15), Abstr. 4064 (2017).

doi: 10.1200/JCO.2017.35.15_suppl.4064

Thadi, A. et al. Early investigations and recent advances in intraperitoneal immunotherapy for peritoneal metastasis. Vaccines 6, 54 (2018).

pmcid: 6160982 doi: 10.3390/vaccines6030054

Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636–2644 (2003).

pubmed: 12860938 doi: 10.1200/JCO.2003.11.136

Jänne, P. A. et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin. Lung Cancer 7, 40–46 (2005).

pubmed: 16098243 doi: 10.3816/CLC.2005.n.020

Carteni, G. et al. Malignant peritoneal mesothelioma — results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 64, 211–218 (2009).

pubmed: 19042053 doi: 10.1016/j.lungcan.2008.08.013

Obasaju, C. K. et al. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program. Lung Cancer 55, 187–194 (2007).

pubmed: 17092602 doi: 10.1016/j.lungcan.2006.09.023

Kepenekian, V. et al. Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE database: multi-institutional retrospective study. Eur. J. Cancer 65, 69–79 (2016).

pubmed: 27472649 doi: 10.1016/j.ejca.2016.06.002

Deraco, M., Baratti, D., Hutanu, I., Bertuli, R. & Kusamura, S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann. Surg. Oncol. 20, 1093–1100 (2013).

pubmed: 23456386 doi: 10.1245/s10434-012-2845-x

Naffouje, S. A., Tulla, K. A. & Salti, G. I. The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking. Med. Oncol. 35, 69 (2018).

pubmed: 29651664 doi: 10.1007/s12032-018-1125-4

Disselhorst, M. J. et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir. Med. 7, 260–270 (2019).

pubmed: 30660511 doi: 10.1016/S2213-2600(18)30420-X

Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397, 375–386 (2021).

pubmed: 33485464 doi: 10.1016/S0140-6736(20)32714-8

Raghav, K. et al. Clinical efficacy of immune checkpoint inhibitors in patients with advanced malignant peritoneal mesothelioma. JAMA Netw. Open 4, e2119934 (2021).

pubmed: 34357397 pmcid: 8346939 doi: 10.1001/jamanetworkopen.2021.19934

Maio, M. et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 18, 1261–1273 (2017).

pubmed: 28729154 doi: 10.1016/S1470-2045(17)30446-1

Desai, A. et al. OA08.03 Phase II trial of pembrolizumab (NCT02399371) in previously-treated malignant mesothelioma (MM): final analysis. J. Thorac. Oncol. 13, S339 (2018).

doi: 10.1016/j.jtho.2018.08.277

Fennell, D. A. et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 22, 1530–1540 (2021).

pubmed: 34656227 pmcid: 8560642 doi: 10.1016/S1470-2045(21)00471-X

Blackham, A. U. et al. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J. Surg. Oncol. 109, 740–745 (2014).

pubmed: 24375188 doi: 10.1002/jso.23547

Lu, P. et al. Systemic chemotherapy and survival in patients with metastatic low-grade appendiceal mucinous adenocarcinoma. J. Surg. Oncol. 120, 446–451 (2019).

pubmed: 31236958 pmcid: 6675644 doi: 10.1002/jso.25599

Turner, K. M. et al. Assessment of neoadjuvant chemotherapy on operative parameters and outcome in patients with peritoneal dissemination from high-grade appendiceal cancer. Ann. Surg. Oncol. 20, 1068–1073 (2013).

pubmed: 23456383 doi: 10.1245/s10434-012-2789-1

Lieu, C. H. et al. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann. Oncol. 23, 652–658 (2012).

pubmed: 21653683 doi: 10.1093/annonc/mdr279

Bijelic, L., Kumar, A. S., Stuart, O. A. & Sugarbaker, P. H. Systemic chemotherapy prior to cytoreductive surgery and hipec for carcinomatosis from appendix cancer: impact on perioperative outcomes and short-term survival. Gastroenterol. Res. Pract. 2012, 163284 (2012).

pubmed: 22899903 pmcid: 3412098 doi: 10.1155/2012/163284

Shapiro, J. F. et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer 116, 316–322 (2010).

pubmed: 19904805 doi: 10.1002/cncr.24715

Munoz-Zuluaga, C. A. et al. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin. Eur. J. Surg. Oncol. 45, 1598–1606 (2019).

pubmed: 31109821 doi: 10.1016/j.ejso.2019.05.008

Baratti, D. et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann. Surg. Oncol. 15, 526–534 (2007).

pubmed: 18043976 doi: 10.1245/s10434-007-9691-2

Milovanov, V. et al. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA). Eur. J. Surg. Oncol. 41, 707–712 (2015).

pubmed: 25633641 doi: 10.1016/j.ejso.2015.01.005

Choe, J. H. et al. Improved survival with anti-VEGF therapy in the treatment of unresectable appendiceal epithelial neoplasms. Ann. Surg. Oncol. 22, 2578–2584 (2015).

pubmed: 25582740 doi: 10.1245/s10434-014-4335-9

Kus, T. et al. Prediction of peritoneal recurrence in patients with gastric cancer: a multicenter study. J. Gastrointest. Cancer 52, 634–642 (2021).

pubmed: 32578034 doi: 10.1007/s12029-020-00419-7

Willett, C. G., Tepper, J. E., Cohen, A. M., Orlow, E. & Welch, C. E. Failure patterns following curative resection of colonic carcinoma. Ann. Surg. 200, 685–690 (1984).

pubmed: 6508395 pmcid: 1250581 doi: 10.1097/00000658-198412000-00001

Minton, J. P. et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 55, 1284–1290 (1985).

pubmed: 3971297 doi: 10.1002/1097-0142(19850315)55:6<1284::AID-CNCR2820550622>3.0.CO;2-B

Elias, D. et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann. Surg. 247, 445–450 (2008).

pubmed: 18376188 doi: 10.1097/SLA.0b013e31815f0113

Sugarbaker, P. H. Revised guidelines for second-look surgery in patients with colon and rectal cancer. Clin. Transl. Oncol. 12, 621–628 (2010).

pubmed: 20851803 doi: 10.1007/s12094-010-0567-8

Honoré, C., Goere, D., Souadka, A., Dumont, F. & Elias, D. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann. Surg. Oncol. 20, 183–192 (2013).

pubmed: 23090572 doi: 10.1245/s10434-012-2473-5

Sugarbaker, P. H. Second-look surgery for colorectal cancer: revised selection factors and new treatment options for greater success. Int. J. Surg. Oncol. 2011, 915078 (2011).

pubmed: 22312530

Sammartino, P. et al. Proactive management for gastric, colorectal and appendiceal malignancies: preventing peritoneal metastases with hyperthermic intraperitoneal chemotherapy (HIPEC). Indian J. Surg. Oncol. 7, 215–224 (2016).

pubmed: 27065712 pmcid: 4818609 doi: 10.1007/s13193-016-0497-1

Rekhraj, S. et al. Can intra-operative intraperitoneal free cancer cell detection techniques identify patients at higher recurrence risk following curative colorectal cancer resection: a meta-analysis. Ann. Surg. Oncol. 15, 60–68 (2008).

pubmed: 17909914 doi: 10.1245/s10434-007-9591-5

Katoh, H. et al. Prognostic significance of peritoneal tumour cells identified at surgery for colorectal cancer. Br. J. Surg. 96, 769–777 (2009).

pubmed: 19526618 doi: 10.1002/bjs.6622

Tan, K.-L., Tan, W.-S., Lim, J.-F. & Eu, K.-W. Krukenberg tumors of colorectal origin: a dismal outcome — experience of a tertiary center. Int. J. Colorectal Dis. 25, 233–238 (2009).

pubmed: 19705132 doi: 10.1007/s00384-009-0796-x

Cheynel, N. et al. Incidence, patterns of failure, and prognosis of perforated colorectal cancers in a well-defined population. Dis. Colon Rectum 52, 406–411 (2009).

pubmed: 19333039 doi: 10.1007/DCR.0b013e318197e351

van Santvoort, H. C. et al. Peritoneal carcinomatosis in t4 colorectal cancer: occurrence and risk factors. Ann. Surg. Oncol. 21, 1686–1691 (2014).

pubmed: 24398543 doi: 10.1245/s10434-013-3461-0

Trilling, B. et al. Intraperitoneal-free cancer cells represent a major prognostic factor in colorectal peritoneal carcinomatosis. Dis. Colon Rectum 59, 615–622 (2016).

pubmed: 27270513 doi: 10.1097/DCR.0000000000000589

Bhatt, A. et al. Patients with extensive regional lymph node involvement (pN2) following potentially curative surgery for colorectal cancer are at increased risk for developing peritoneal metastases: a retrospective single-institution study. Colorectal Dis. 21, 287–296 (2019).

pubmed: 30457185 doi: 10.1111/codi.14481

Klaver, C. E. L. et al. Locally advanced colorectal cancer: true peritoneal tumor penetration is associated with peritoneal metastases. Ann. Surg. Oncol. 25, 212–220 (2018).

pubmed: 29076043 doi: 10.1245/s10434-017-6037-6

Arrizabalaga, N. B. et al. Prophylactic HIPEC in pT4 colon tumors: proactive approach or overtreatment? Ann. Surg. Oncol. 27, 1094–1100 (2020).

pubmed: 31664619 doi: 10.1245/s10434-019-07970-z

Veld, J. V. et al. Synchronous and metachronous peritoneal metastases in patients with left-sided obstructive colon cancer. Ann. Surg. Oncol. 27, 2762–2773 (2020).

pubmed: 32170481 pmcid: 7334250 doi: 10.1245/s10434-020-08327-7

Elias, D. et al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann. Surg. 254, 289–293 (2011).

pubmed: 21709543 doi: 10.1097/SLA.0b013e31822638f6

Stewart, C. J. R., Hillery, S. & Plattell, C. Protocol for the examination of specimens from patients with primary carcinomas of the colon and rectum. Arch. Pathol. Lab. Med. 133, 1182–1193 (2009). 1359-60-author reply 1360-1.

doi: 10.5858/133.9.1359

Panarelli, N. C., Schreiner, A. M., Brandt, S. M., Shepherd, N. A. & Yantiss, R. K. Histologic features and cytologic techniques that aid pathologic stage assessment of colonic adenocarcinoma. Am. J. Surg. Pathol. 37, 1252–1258 (2013).

pubmed: 23774176 doi: 10.1097/PAS.0b013e3182960e7c

Frankel, W. L. & Jin, M. Serosal surfaces, mucin pools, and deposits, oh my: challenges in staging colorectal carcinoma. Mod. Pathol. 28 (Suppl. 1), S95–S108 (2015).

pubmed: 25560604 doi: 10.1038/modpathol.2014.128

Klaver, C. E. L. et al. Interobserver, intraobserver, and interlaboratory variability in reporting pT4a colon cancer. Virchows Arch. 476, 219–230 (2019).

pubmed: 31616981 pmcid: 7028812 doi: 10.1007/s00428-019-02663-0

Sun, Z. et al. A novel subclassification of pT2 gastric cancers according to the depth of muscularis propria invasion. Ann. Surg. 249, 768–775 (2009).

pubmed: 19387327 doi: 10.1097/SLA.0b013e3181a3df77

Park, D. J. et al. Subclassification of pT2 gastric adenocarcinoma according to depth of invasion (pT2a vs pT2b) and lymph node status (pN). Surgery 141, 757–763 (2007).

pubmed: 17560252 doi: 10.1016/j.surg.2007.01.023

Klaver, C. E. L. et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol. Hepatol. 4, 761–770 (2019).

pubmed: 31371228 doi: 10.1016/S2468-1253(19)30239-0

Baratti, D. et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of primary curative surgery in patients with colorectal cancer at high risk for metachronous peritoneal metastases. Ann. Surg. Oncol. 24, 167–175 (2017).

pubmed: 27519353 doi: 10.1245/s10434-016-5488-5

Koh, J.-L., Yan, T. D., Glenn, D. & Morris, D. L. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann. Surg. Oncol. 16, 327–333 (2009).

pubmed: 19050972 doi: 10.1245/s10434-008-0234-2

Nordlinger, B. et al. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial. Lancet Oncol. 6, 459–468 (2005).

pubmed: 15992694 doi: 10.1016/S1470-2045(05)70222-9

Sloothaak, D. A. M. et al. Intraperitoneal chemotherapy as adjuvant treatment to prevent peritoneal carcinomatosis of colorectal cancer origin: a systematic review. Br. J. Cancer 111, 1112–1121 (2014).

pubmed: 25025964 pmcid: 4453838 doi: 10.1038/bjc.2014.369

Bennouna, J. et al. Rationale and design of the IROCAS study: multicenter, international, randomized phase 3 trial comparing adjuvant modified (m) FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer — A UNICANCER GI-PRODIGE Trial. Clin. Colorectal Cancer 18, e69–e73 (2019).

pubmed: 30415988 doi: 10.1016/j.clcc.2018.09.011

Al-Batran, S.-E. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393, 1948–1957 (2019).

pubmed: 30982686 doi: 10.1016/S0140-6736(18)32557-1

Arjona-Sánchez, Á. et al. HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of hyperthermic intra-peritoneal chemotherapy (HIPEC) with mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC cancer 18, 183–188 (2018).

pubmed: 29439668 pmcid: 5812226 doi: 10.1186/s12885-018-4096-0

Koga, S. et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 61, 232–237 (1988).

pubmed: 3121165 doi: 10.1002/1097-0142(19880115)61:2<232::AID-CNCR2820610205>3.0.CO;2-U

Zhu, L. et al. Prophylactic chemotherapeutic hyperthermic intraperitoneal perfusion reduces peritoneal metastasis in gastric cancer: a retrospective clinical study. BMC Cancer 20, 827 (2020).

pubmed: 32867714 pmcid: 7461269 doi: 10.1186/s12885-020-07339-6

Yonemura, Y. et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterol 48, 1776–1782 (2001).

Brenkman, H. J. F., Päeva, M., Hillegersberg, R., van, Ruurda, J. P. & Mohammad, N. H. Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer — a systematic review. J. Clin. Med. 8, 1685 (2019).

pmcid: 6832700 doi: 10.3390/jcm8101685

Glehen, O. et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer 14, 183 (2014).

pubmed: 24628950 pmcid: 3995601 doi: 10.1186/1471-2407-14-183

Argani, P. et al. Pediatric mesothelioma with ALK fusions. Am. J. Surg. Pathol. 45, 653–661 (2021).

pubmed: 33399341 pmcid: 8035308 doi: 10.1097/PAS.0000000000001656

Desmeules, P. et al. A subset of malignant mesotheliomas in young adults are associated with recurrent EWSR1/FUS-ATF1 fusions. Am. J. Surg. Pathol. 41, 980–988 (2017).

pubmed: 28505004 pmcid: 5468482 doi: 10.1097/PAS.0000000000000864

Argani, P. et al. EWSR1/FUS-CREB fusions define a distinctive malignant epithelioid neoplasm with predilection for mesothelial-lined cavities. Mod. Pathol. 33, 2233–2243 (2020).

pubmed: 32770123 pmcid: 7584759 doi: 10.1038/s41379-020-0646-5

Raghav, K. et al. Efficacy, safety and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma. Cancer Discov. 11, 2738–2747 (2021).

pubmed: 34261675 pmcid: 8563380 doi: 10.1158/2159-8290.CD-21-0331

Khanna, S. et al. Malignant mesothelioma effusions are infiltrated by CD3

pubmed: 27544053 pmcid: 5075512 doi: 10.1016/j.jtho.2016.07.033

Valmary-Degano, S. et al. Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: a RENAPE study. Eur. J. Surg. Oncol. 43, 1915–1923 (2017).

pubmed: 28619621 doi: 10.1016/j.ejso.2017.05.009

Chapel, D. B. et al. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. Hum. Pathol. 87, 11–17 (2019).

pubmed: 30794891 doi: 10.1016/j.humpath.2019.02.001

Arjona-Sánchez, Á. et al. A proposal for modification of the PSOGI classification according to the Ki-67 proliferation index in pseudomyxoma peritonei. Ann. Surg. Oncol. 29, 126–136 (2022).

pubmed: 34215955 doi: 10.1245/s10434-021-10372-9

Tokunaga, R. et al. Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer. Clin. Cancer Res. 25, 3096–3103 (2019).

pubmed: 30692096 pmcid: 6886223 doi: 10.1158/1078-0432.CCR-18-3388

Koopman, M. et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br. J. Cancer 100, 266–273 (2009).

pubmed: 19165197 pmcid: 2634718 doi: 10.1038/sj.bjc.6604867

Liu, X. et al. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. Pathol. Res. Pract. 216, 152881 (2020).

pubmed: 32089413 doi: 10.1016/j.prp.2020.152881

Fuchs, C. S. et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 Trial. JAMA Oncol. 4, e180013 (2018).

pubmed: 29543932 pmcid: 5885175 doi: 10.1001/jamaoncol.2018.0013

Wang, F. et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann. Oncol. 30, 1479–1486 (2019).

pubmed: 31236579 pmcid: 6771223 doi: 10.1093/annonc/mdz197

Drakes, M. L. et al. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer. J. Ovarian Res. 11, 43 (2018).

pubmed: 29843813 pmcid: 5975524 doi: 10.1186/s13048-018-0414-z

Hamanishi, J. et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8

pubmed: 17360651 pmcid: 1805580 doi: 10.1073/pnas.0611533104

Verwaal, V. J. et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J. Clin. Oncol. 21, 3737–3743 (2003).

pubmed: 14551293 doi: 10.1200/JCO.2003.04.187

Verwaal, V. J., Bruin, S., Boot, H., van Slooten, G. & van Tinteren, H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann. Surg. Oncol. 15, 2426–2432 (2008).

pubmed: 18521686 doi: 10.1245/s10434-008-9966-2

Cashin, P. H. et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur. J. Cancer 53, 155–162 (2016).

pubmed: 26751236 doi: 10.1016/j.ejca.2015.09.017

Lemoine, L. et al. Body surface area-based vs concentration-based perioperative intraperitoneal chemotherapy after optimal cytoreductive surgery in colorectal peritoneal surface malignancy treatment: COBOX trial. J. Surg. Oncol. 119, 999–1010 (2019).

pubmed: 30838646 doi: 10.1002/jso.25437

Zivanovic, O. et al. Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study. J. Clin. Oncol. 39, 2594–2604 (2021).

pubmed: 34019431 pmcid: 8330970 doi: 10.1200/JCO.21.00605

Fagotti, A. et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int. J. Gynecol. Cancer 30, 1657–1664 (2020).

pubmed: 33028623 doi: 10.1136/ijgc-2020-001640

Lim, M. C. et al. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer. JAMA Surg. 157, 374–383 (2022).

pubmed: 35262624 pmcid: 8908225 doi: 10.1001/jamasurg.2022.0143

Levine, E. A. et al. A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. J. Am. Coll. Surg. 226, 434–443 (2018).

pubmed: 29331663 pmcid: 5890298 doi: 10.1016/j.jamcollsurg.2017.12.027

Wallner, K. E., Banda, M. & Li, G. C. Hyperthermic enhancement of cell killing by mitomycin C in mitomycin C-resistant Chinese hamster ovary cells. Cancer Res. 47, 1308–1312 (1987).

pubmed: 3102043

Harrison, L. E., Bryan, M., Pliner, L. & Saunders, T. Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy. Ann. Surg. Oncol. 15, 1407–1413 (2008).

pubmed: 18157576 doi: 10.1245/s10434-007-9718-8

Huang, Y., Alzahrani, N. A., Liauw, W., Traiki, T. B. & Morris, D. L. Early postoperative intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasms with pseudomyxoma peritonei: is it beneficial? Ann. Surg. Oncol. 24, 176–183 (2017).

pubmed: 27718032 doi: 10.1245/s10434-016-5529-0

Sugarbaker, P. H. & Chang, D. Cytoreductive surgery plus HIPEC with and without NIPEC for malignant peritoneal mesothelioma: a propensity-matched analysis. Ann. Surg. Oncol. 28, 7109–7117 (2021).

pubmed: 33942167 doi: 10.1245/s10434-021-10048-4

Advances in the management of peritoneal malignancies.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Pagination

Informations de copyright

Références

Auteurs

Vahan Kepenekian (V)

Aditi Bhatt (A)

Julien Péron (J)

Mohammad Alyami (M)

Nazim Benzerdjeb (N)

Naoual Bakrin (N)

Claire Falandry (C)

Guillaume Passot (G)

Pascal Rousset (P)

Olivier Glehen (O)

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Smoking Cessation and Incident Cardiovascular Disease.

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Classifications MeSH